Tech Company Financing Transactions
Rheos Medicines Funding Round
Rheos Medicines secured a $60 million Series A venture capital round on 3/23/2018. Backers included Third Rock Ventures.
Transaction Overview
Company Name
Announced On
3/23/2018
Transaction Type
Venture Equity
Amount
$60,000,000
Round
Series A
Investors
Proceeds Purpose
The company will translate recent breakthroughs in the understanding of immune cell metabolism to develop precision medicines for immune-mediated diseases.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
245 1st St. 200
Cambridge, MA 02142
USA
Cambridge, MA 02142
USA
Phone
Website
Email Address
Overview
We are leading the way in the emerging field of immunometabolism to develop novel, precision medicines to treat patients with immune-mediated diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Barbara Fox
Chief Scientific Officer
Dania Rabah
Chief Technical Officer
Edward Driggers
Vice President
Andrew Long
VP - Finance
Kevin Lewtas
VP - Human Resources
Colleen Wilson
Browse more venture capital transactions:
Prev: 3/23/2018: Amper Music venture capital transaction
Next: 3/23/2018: BioIQ venture capital transaction
Share this article
News on VC Transactions
Our team works diligently to report on tech company VC transactions. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs